Is recurrent vaginal melanoma a lethal disease?

Journal of the Chinese Medical Association

Volumn 74, Issue 8, 2011, Pages 333-

  Wang, Peng Hui ^a   Sheu, Bor Ching ^b,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CELECOXIB; CYTOTOXIC AGENT; PACLITAXEL;

ANTIANGIOGENIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CONTINUOUS INFUSION; EDITORIAL; FEMALE; HUMAN; MELANOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; VAGINAL MELANOMA; VULVECTOMY;

BRAIN NEOPLASMS; FEMALE; HUMANS; MELANOMA; NEOPLASM RECURRENCE, LOCAL; VAGINAL NEOPLASMS;

EID: 80052091853     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2011.06.003     Document Type: Editorial

References (4)

1. Lin L.T., Liu C.B., Chen S.N., Chiang A.J., Liou W.S., Yu K.J. Primary malignant melanoma of the vagina with repeat local recurrences and brain metastasis: a case report and review of the current treatment. J Chin Med Assoc 2011, 74:376-379.
2. Frumovitz M., Etchepareborda M., Sun C.C., Soliman P.T., Eifel P.J., Levenback C.F., et al. Primary malignant melanoma of the vagina. Obstet Gynecol 2010, 116:1358-1365.
3. Mutsaers A.J. Metronomic chemotherapy. Top Companion Anim Med 2009, 24:137-143.
4. Bhatt R.S., Merchan J., Parker R., Wu H.K., Zhang L., Seery V., et al. A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer 2010, 116:1751-1756.